← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Bioaxone Biosciences, Inc.
Boston, MA
$6,099,702
Total funding
6
Grants
Funding over time
peak $2.3M · FY2014–18$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$6,099,702 · 6
By mechanism
R44$5,307,061 · 3
R43$792,641 · 3
Investigators at Bioaxone Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of BA-1049 for treatment of cerebral cavernous malformation$1,576,432
R44 · FY2017 · NS
Development of BA-1049 for treatment of cerebral cavernous malformation$1,430,655
R44 · FY2016 · NS
Development of self-delivering RNAi targeted to PTEN for treatment of spinal cord injury$1,059,073
R44 · FY2018 · NS
Development of self-delivering RNAi targeted to PTEN for treatment of spinal cord injury$735,822
R44 · FY2017 · NS
Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury$319,201
R43 · FY2015 · NS
Development of BA-1049 for treatment of cerebral cavernous malformation$280,625
R44 · FY2016 · NS
Development of self-delivering RNAi to evaluate PTEN as a therapeutic target to p$224,789
R43 · FY2014 · NS
An oral ROCK2-selective inhibitor for treatment of chronic spinal cord injury$224,454
R44 · FY2018 · NS
Investigation of PEGylated BA-210 for RGC neuroprotection$223,651
R43 · FY2014 · EY
Regulatory development of PEGylated BA-210 for RGC neuroprotection$25,000
R43 · FY2014 · EY